Abstract
The international drug development environment is characterized by tremendous pressure to reduce health care costs, increasing government regulations, longer product development time, and shorter marketing exclusivity. Throughout the 1980s and 1990s many pharmaceutical companies and regulatory agencies have shown a commitment to the exploration and implementation of new technologies and to the establishment of open systems for the electronic exchange and review of regulatory information. The major electronic standards initiatives, Drug Application Methodology with Optical Storage (DAMOS), Multi Agency Electronic Regulatory Submission (MERS), Market Authorization by Network Submission and Evaluation (MANSEV), Electronic Submission for Market Authorization (SEDAMM), and the ICH Multidisciplinary Group (ICH-M2) on Electronic Standards for the Transfer of Regulatory Information, have very similar goals. There are very few differences among the standards initiatives at the highest level of the submission struc...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call